Skip to main content
SpringerLink
Log in

Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination

  • Chapter
  • First Online:
Pathology of Peritoneal Metastases

Abstract

Mesothelioma is a rare neoplasm arising from the mesothelial cells lining the pleura, peritoneum, pericardium, and tunica vaginalis layer of testis [1]. Diffuse malignant peritoneal mesothelioma (DMPM) represents about one-fifth to one-third of all forms of mesothelioma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Robinson BWS, Lake RA. Advanced in malignant mesothelioma. N Engl J Med. 2005;353:1591–603.

    CAS  PubMed  Google Scholar 

  2. Conti S, Minelli G, Ascoli V, Marinaccio A, Bonafede M, Manno V, Crialesi R, Straif K. Peritoneal mesothelioma in Italy: trends and geography of mortality and incidence. Am J Ind Med. 2015;58:1050–8.

    PubMed  Google Scholar 

  3. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985–90.

    CAS  PubMed  Google Scholar 

  4. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.

    PubMed  Google Scholar 

  5. Gazdar AF, Carbone M. Molecular pathogenesis of mesothelioma and its relationship to Simian virus 40. Clin Lung Cancer. 2003;5:177–81.

    PubMed  Google Scholar 

  6. Roushdy-Hammady I, Siegel J, Emri S, et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001;357:444–5.

    CAS  PubMed  Google Scholar 

  7. Churg A, Roggli VL, Galateau-Salle F, et al. Tumours of the pleura: mesothelial tumours. In: Travis WD, Brambilla E, Harris CC, Muller-Hermelink HK, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.

    Google Scholar 

  8. Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2018;142:89–108.

    CAS  PubMed  Google Scholar 

  9. Battifora H, McCaughey WTE. Tumours and pseudotumours of the serosal membranes. In: Atlas of tumour pathology 3rd series, fascicle 15. Washington, DC: Armed Forces Institute of Pathology; 1995. p. 15–88.

    Google Scholar 

  10. Roggli VL, Cagle PT. Pleura, pericardium and peritoneum. In: Silverberg SG, DeLellis RA, Frable WJ, LiVolsi VA, Wick MR, editors. Silverberg’s principles and practice of surgical pathology. 4th ed. New York: Churchill-Livingstone/Elsevier; 2006. p. 1005–39.

    Google Scholar 

  11. Allen TC, Cagle PT, Churg AM, Colby TV, Gibbs AR, Hammar SP, Corson JM, Grimes MM, Ordonez NG, Roggli V, Travis WD, Wick MR. Localized malignant mesothelioma. Am J Surg Pathol. 2005;29:7.

    Google Scholar 

  12. Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17:45–53.

    PubMed  Google Scholar 

  13. Butnor KJ, Sporn TA, Hammar SP, Roggli VL. Well-differentiated papillary mesothelioma. Am J Surg Pathol. 2001;25:1304–9.

    CAS  PubMed  Google Scholar 

  14. Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol. 2007;14:2790–7.

    CAS  PubMed  Google Scholar 

  15. de Pangher V, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21:348–53.

    Google Scholar 

  16. Park JY, Kim KW, Kwon HJ, et al. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. Am J Roentgenol. 2008;191:814–25.

    Google Scholar 

  17. Whitley N, Brenner D, Antman K, Grant D, Aisner J. CT of peritoneal mesothelioma: analysis of eight cases. Am J Roentgenol. 1982;138:531–5.

    CAS  Google Scholar 

  18. Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103:839–49.

    PubMed  Google Scholar 

  19. Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14:500–8.

    PubMed  Google Scholar 

  20. Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, Guaglio M, Kusamura S, Deraco M. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: a preliminary study. Eur J Surg Oncol. 2018;44:792–8.

    PubMed  Google Scholar 

  21. Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo. 2009;23:187–90.

    PubMed  Google Scholar 

  22. Churg A, Colby TV, Cagle P. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24:1183–200.

    CAS  PubMed  Google Scholar 

  23. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43:231–8.

    CAS  PubMed  Google Scholar 

  24. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129:1407–14.

    PubMed  Google Scholar 

  25. Rogoff EE, Hilaris B, Huvos AG. Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer. 1973;32:656–64.

    CAS  PubMed  Google Scholar 

  26. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med. 1982;96:746–55.

    CAS  PubMed  Google Scholar 

  27. Antman KH, Osteen R, Klegar K, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2:977–81.

    CAS  PubMed  Google Scholar 

  28. Kirmani S, Cleary SM, Mowry J, et al. Intracavitary cisplatin for malignant mesothelioma: an update. Proc Am Clin Oncol. 1988;7. (Abstract 1057).

    Google Scholar 

  29. van Gelder T, Hoogsteden HC, Versnel MA, et al. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion. 1989;43:222–7.

    PubMed  Google Scholar 

  30. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547–50.

    CAS  PubMed  Google Scholar 

  31. Neumann V, Muller KM, Fischer M. Peritoneal mesothelioma-incidence and aetiology. Pathologe. 1999;20:169–76.

    CAS  PubMed  Google Scholar 

  32. Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.

    CAS  PubMed  Google Scholar 

  33. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19:1416–24.

    PubMed  Google Scholar 

  35. Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321–8.

    PubMed  Google Scholar 

  36. Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58.

    Google Scholar 

  37. Blackham AU, Shen P, Stewart JH, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010;17:1720–7.

    Google Scholar 

  38. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.

    CAS  PubMed  Google Scholar 

  39. Robella M, Vaira M, Mellano A, et al. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. Minerva Chir. 2014;69:9–15.

    CAS  PubMed  Google Scholar 

  40. Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11:3303–8.

    CAS  PubMed  Google Scholar 

  41. Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654–61.

    PubMed  Google Scholar 

  42. Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007;31:784–8.

    PubMed  Google Scholar 

  43. Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99:109–13.

    PubMed  Google Scholar 

  44. Gilani SNS, Mehta A, Garcia-Fadrique A, et al. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. Int J Hyperthermia. 2018;34:578–84.

    PubMed  Google Scholar 

  45. Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49:3140–8.

    PubMed  Google Scholar 

  46. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma—a multi-institutional registry study. J Clin Oncol. 2009;27:6237–42.

    PubMed  Google Scholar 

  47. Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779–86.

    PubMed  PubMed Central  Google Scholar 

  48. Hommell-Fontaine J, Isaac S, Passot G, et al. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Ann Surg Oncol. 2013;20:3892–8.

    CAS  PubMed  Google Scholar 

  49. Magge D, Zenati MS, Austin F, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21:1159–65.

    PubMed  Google Scholar 

  50. Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol. 2015;22:1680–5.

    PubMed  Google Scholar 

  51. Malgras B, Gayat E, Aoun O, et al. Impact of combination chemotherapy in peritoneal mesothelioma Hyperthermic Intraperitoneal chemotherapy (HIPEC): the RENAPE study. Ann Surg Oncol. 2018;25:3271–9.

    PubMed  Google Scholar 

  52. Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma—results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–8.

    CAS  PubMed  Google Scholar 

  53. Jänne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40–6.

    PubMed  Google Scholar 

  54. Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008;26:3567–72.

    CAS  PubMed  Google Scholar 

  55. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093–100.

    PubMed  Google Scholar 

  56. Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69–79.

    CAS  PubMed  Google Scholar 

  57. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117:1855–63.

    PubMed  Google Scholar 

  58. Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol. 2013;20:555–61.

    PubMed  Google Scholar 

  59. Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Malignancy Group. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol. 2012;23:1494–8.

    CAS  PubMed  Google Scholar 

  60. Votanopoulos KI, Sugarbaker P, Deraco M, et al. Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the peritoneal surface oncology group international registry. Ann Surg Oncol. 2018;25:667–73.

    PubMed  Google Scholar 

  61. Valmary-Degano S, Colpart P, Villeneuve L, et al. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study. Eur J Surg Oncol. 2017;43:1915–23.

    CAS  PubMed  Google Scholar 

  62. Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A, Kusamura S, Baratti D, Deraco M, Costa A, Reddel RR, Zaffaroni N. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2008;14:4134–40.

    CAS  PubMed  Google Scholar 

  63. Huang Y, Alzahrani NA, Liauw W, Morris DL. Effects of sex hormones on survival of peritoneal mesothelioma. World J Surg Oncol. 2015;13:210.

    PubMed  PubMed Central  Google Scholar 

  64. Pillai K, Pourgholami MH, Chua TC, Morris DL. Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. Am J Cancer Res. 2013;3:411–23.

    PubMed  PubMed Central  Google Scholar 

  65. Pillai K, Pourgholami MH, Chua TC, Morris DL. MUC1 has prognostic significance in malignant peritoneal mesothelioma. Int J Biol Markers. 2013;28:303–12.

    CAS  PubMed  Google Scholar 

  66. Singhi AD, Krasinskas AM, Choudry HA, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol. 2016;29:14–24.

    CAS  PubMed  Google Scholar 

  67. Krasinskas AM, Borczuk AC, Hartman DJ, et al. Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology. 2016;68:729–37.

    PubMed  Google Scholar 

  68. Li YC, Khashab T, Terhune J, et al. Preoperative thrombocytosis predicts shortened survival in patients with malignant peritoneal mesothelioma undergoing operative Cytoreduction and Hyperthermic Intraperitoneal chemotherapy. Ann Surg Oncol. 2017;24:2259–65.

    PubMed  Google Scholar 

  69. Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol. 2016;23:1468–73.

    PubMed  Google Scholar 

  70. Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D, Deraco M, Daidone MG. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol. 2007;29:453–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Carbone A, Pennati M, Parrino B, et al. Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models. J Med Chem. 2013;56:7060–72.

    CAS  PubMed  Google Scholar 

  72. De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, Friedlander S, Landesman Y, Kauffman MG, Shacham S, Pennati M, Zaffaroni N. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget. 2015;6:13119–32.

    PubMed  PubMed Central  Google Scholar 

  73. Perrone F, Jocollè G, Pennati M. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer. 2010;46:2837–48.

    CAS  PubMed  Google Scholar 

  74. Varghese S, Chen Z, Bartlett DL, et al. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2011;117:361–71.

    CAS  PubMed  Google Scholar 

  75. Bozzi F, Brich S, Dagrada GP, Negri T, Conca E, Cortelazzi B, Belfiore A, Perrone F, Gualeni AV, Gloghini A, Cabras A, Brenca M, Maestro R, Zaffaroni N, Casali P, Bertulli R, Deraco M, Pilotti S. Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. Oncotarget. 2016;7:75503–17.

    PubMed  PubMed Central  Google Scholar 

  76. Govindan R, Kratzke RA, Herndon JE 2nd, et al., Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B Clin Cancer Res. 2005;11:2300–4.

    Google Scholar 

  77. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007;25:2406–13.

    CAS  PubMed  Google Scholar 

  78. Dolly SO, Migali C, Tunariu N, et al. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. ESMO Open. 2017;e000101:2.

    Google Scholar 

  79. Alakus H, Yost SE, Woo B, et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med. 2015;13:122.

    PubMed  PubMed Central  Google Scholar 

  80. Joseph NM, Chen YY, Nasr A, et al. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod Pathol. 2017;30:246–54.

    CAS  PubMed  Google Scholar 

  81. Chirac P, Maillet D, Lepretre F, et al. Genomic copy alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array. Hum Pathol. 2016;55:72–82.

    CAS  PubMed  Google Scholar 

  82. Leblay N, Leprêtre F, Le Stang N, et al. BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J Thorac Oncol. 2017;12:724–33.

    PubMed  Google Scholar 

  83. Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:1043–57.

    CAS  PubMed  Google Scholar 

  84. Andrici J, Sheen A, Sioson L, et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol. 2015;28:1360–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Shrestha R, Nabavi N, Lin YY, et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 2019;11:8.

    PubMed  PubMed Central  Google Scholar 

  86. Sacco JJ, Kenyani J, Butt Z, et al. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors. Oncotarget. 2015;6:13757–71.

    PubMed  PubMed Central  Google Scholar 

  87. LaFave LM, Béguelin W, Koche R, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21:1344–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6:451–60.

    PubMed  Google Scholar 

  89. Khanna S, Thomas A, Abate-Daga D, Zhang J, et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol. 2016;11:1993–2005.

    PubMed  PubMed Central  Google Scholar 

  90. Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Hum Pathol. 2019;87:11–7.

    CAS  PubMed  Google Scholar 

  91. Hung YP, Dong F, Watkins JC, et al. Identification of alk rearrangements in malignant peritoneal mesothelioma. JAMA Oncol. 2018;4:235–8.

    PubMed  Google Scholar 

  92. Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407–16.

    CAS  PubMed  Google Scholar 

  93. Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, et al. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine. 2019;39:215–25.

    PubMed  Google Scholar 

  94. Birnie KA, Prêle CM, Thompson PJ, Badrian B, Mutsaers SE. Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma. Oncotarget. 2017;8:78193–207.

    PubMed  PubMed Central  Google Scholar 

  95. El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco V, Zaffaroni N. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol. 2017;10:19.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Peritoneal Surface Malignancy Unit, Department of Surgery, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

    Marcello Deraco, Shigeki Kusamura, Marcello Guaglio, Matteo Montenovo & Dario Baratti

  2. Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

    Nadia Zaffaroni

  3. Department of Pathology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

    Federica Perrone & Antonello Cabras

Authors
  1. Marcello Deraco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadia Zaffaroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Federica Perrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonello Cabras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shigeki Kusamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marcello Guaglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Matteo Montenovo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dario Baratti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcello Deraco .

Editor information

Editors and Affiliations

  1. General and Oncologique Surgery, Centre Hospitalier Lyon-Sud, Lyon, France

    Olivier Glehen

  2. Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India

    Aditi Bhatt

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Deraco, M. et al. (2020). Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination. In: Glehen, O., Bhatt, A. (eds) Pathology of Peritoneal Metastases. Springer, Singapore. https://doi.org/10.1007/978-981-15-3773-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-3773-8_6

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-3772-1

  • Online ISBN: 978-981-15-3773-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation